iStent Inject Versus Goniotomy With Kahook Dual Blade in Glauocma Treatment

Glaucoma patients with significant cataract are being informed about the study and potential risks, all participants giving written informed consent and meeting the criteria will become eligibility for study entry. Participants meeting the eligible requirements will be randomized to Cataract Surgery combined with Kahook Dual Blade Glide (50 patients) or iStent Inject W (50 patients).

• Goniotomy with KDB blade goniotomy (Device): Goniotomy with KDB glide will be performed at the end of Cataract Surgery through the temporal cataract incision.
• Two iStent inject implanation (Device): The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.

Primary outcomes

• Change in the number of intraocular pressure lowering medications compared to baseline [From enrollment to the end of treatment at 12 months]: Accountability of intraocular pressure lowering medications used by the patient
• Intraocular pressure measured by Goldmann applanation tonometry (GAT) [From enrollment to the end of treatment at 12 months]: Number of participants with ≥20 percent intraocular pressure reduction or reduction with ≥1 medication compared to baseline

Secondary outcomes

• Number of participants with intraocular pressure ≤21 mm Hg, ≤18 mm Hg, ≤15 mm Hg and ≤12mm Hg [From enrollment to the end of treatment at 12 months]: Intraocular pressure measured by Goldmann applanation tonometry (GAT) at 12 months

Sex: All, ages: 18 Weeks to any

Inclusion Criteria:

* Only one eye per participant
* Clinically significant cataract
* Glaucoma or intraocular hypertension treated with one to four medications and no need for filtering glaucoma surgery at the time of study enrollment.
* Open chamber angle with Schaffer grading three to four in at least two quadrants

Exclusion Criteria:

* Previous glaucoma surgery, including cyclodestructive procedures.
* Selective Laser Trabeculoplasty (SLT) within 90 days prior to planned surgery.
* Exudative age-related macular degeneration, proliferative diabetic retinopathy, clinically significant corneal dystrophy, other eye disease that affect intraocular eye pressure or visual field.
* Unable to participate and make written consent due to another medical condition.